In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' is Covered under Japanese Insurance Program, effective as of August.

In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' is Covered under Japanese Insurance Program, effective as of August.
[ 2011/08/08 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceuticals | Tokyo | Non-listed ]

The Company's Official Page
http://www.otsuka.co.jp/en/release/2011/0808_01.html

Back To Previous Page

Otsuka Pharmaceutical Co., Ltd.

August 8, 2011

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that its WT1 mRNA Assay KitO 'tsuka', an in-vitro diagnostic kit by the quantitative real time RT-PCR method is now covered under the Japanese national health insurance program, effective on August 1, 2011, for Myelodysplastic Syndromes (MDS) in addition to Acute Myeloid Leukemia (AML).

Latest News: Pharmaceuticals

この内容でのリリース掲載はまだ無いか、集計されておりません。

1.	Otsuka Pharmaceutical Files for Addition... Otsuka Pharmaceutical Co., Ltd. 2011/01/24
2.	Supplementary Financial Data ... Sumitomo Pharma Co., Ltd. 2009/05/11
3.	Notice of launching of a new Parkinson&#... Sumitomo Pharma Co., Ltd. 2009/03/13
4.	Parkinson's disease drug "TRER... Sumitomo Pharma Co., Ltd. 2009/01/21
5.	Kaken licenses out Fiblast® Spray in... Kaken Pharmaceutical Co.,Ltd. 2005/12/20

Latest News: Otsuka Pharmaceutical Co., Ltd.

この内容でのリリース掲載はまだ無いか、集計されておりません。

1.	World's First Aquaretic Agent for t... 2010/12/10
2.	The European Medicines Agency (EMA) Appr... 2013/02/06